Abstract
Type 2 diabetes is a heterogeneous disease with large variation in the relative contributions of insulin resistance and beta cell dysfunction between subgroups and individuals. Some of these differences are reflected in the way people are diagnosed. However, differences in glucose regulation exist among individuals even in those with comparable diagnostic glucose levels. In this review we address the heterogeneity of pre-diabetes and type 2 diabetes with special emphasis on differences in the pathophysiology and treatment responses related to the diagnostic criteria. We also discuss whether novel glycaemic markers of diabetes risk can provide additional information to the established diagnostic criteria. A better understanding of the underlying mechanisms responsible for elevated fasting versus postprandial glucose concentration, as well as knowledge about the expected responsiveness to treatment in individuals with different clinical characteristics at diagnosis, may contribute to optimising strategies for management of hyperglycaemia in both pre-diabetes and type 2 diabetes.
Keywords: Beta cell dysfunction, diabetes management, diabetes prediction, diagnostic criteria, fasting glucose, insulin resistance, obesity, physical activity, postprandial glucose, weight loss.
Current Diabetes Reviews
Title:Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness
Volume: 12 Issue: 1
Author(s): Kristine Faerch, Adam Hulman and Thomas P.J. Solomon
Affiliation:
Keywords: Beta cell dysfunction, diabetes management, diabetes prediction, diagnostic criteria, fasting glucose, insulin resistance, obesity, physical activity, postprandial glucose, weight loss.
Abstract: Type 2 diabetes is a heterogeneous disease with large variation in the relative contributions of insulin resistance and beta cell dysfunction between subgroups and individuals. Some of these differences are reflected in the way people are diagnosed. However, differences in glucose regulation exist among individuals even in those with comparable diagnostic glucose levels. In this review we address the heterogeneity of pre-diabetes and type 2 diabetes with special emphasis on differences in the pathophysiology and treatment responses related to the diagnostic criteria. We also discuss whether novel glycaemic markers of diabetes risk can provide additional information to the established diagnostic criteria. A better understanding of the underlying mechanisms responsible for elevated fasting versus postprandial glucose concentration, as well as knowledge about the expected responsiveness to treatment in individuals with different clinical characteristics at diagnosis, may contribute to optimising strategies for management of hyperglycaemia in both pre-diabetes and type 2 diabetes.
Export Options
About this article
Cite this article as:
Faerch Kristine, Hulman Adam and Solomon P.J. Thomas, Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness, Current Diabetes Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573399811666150416122903
DOI https://dx.doi.org/10.2174/1573399811666150416122903 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Molecule of the Month
Current Topics in Medicinal Chemistry Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects
Current Pharmaceutical Design Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease
Current Hypertension Reviews Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry A Comprehensive Review on the Biological and Pharmacological Activities of Rhodanine Based Compounds for Research and Development of Drugs
Mini-Reviews in Medicinal Chemistry Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design The Coronin Family and Human Disease
Current Protein & Peptide Science Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Chromatographic Fingerprinting and Metabolomics for Quality Control of TCM
Combinatorial Chemistry & High Throughput Screening Diet and Cardiovascular Disease: Effects of Foods and Nutrients in Classical and Emerging Cardiovascular Risk Factors
Current Medicinal Chemistry Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research A Micro-Aggregation Algorithm Based on Density Partition Method for Anonymizing Biomedical Data
Current Bioinformatics Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Marine Algae As A Prospective Source For Antidiabetic Compounds – A Brief Review
Current Diabetes Reviews Recent Advances in the Management of Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Experimental Antiarrhythmic Targets: CaMKII Inhibition – Ready for Clinical Evaluation?
Current Medicinal Chemistry